Baidu
map

Crit Care Med:严重脓毒症患者再次入院频率,费用及相关风险因素研究

2015-04-04 MedSci MedSci原创

目标:我们进行该研究的目的是探究因为严重败血症的患者再次入院的频率、死亡率、医疗费用和相关风险因素。设计:该研究为观察性队列研究,且不采取任何干预措施。数据来源于医疗保健花销与利用数据库。地点:实验在美国三个州的所有非联邦医院进行。参与人员:2011年前两个季度的共43452位严重败血症的患者。结果:我们获得了严重败血症患者再入院的比例、相关花销和再入院后死亡率等相关数据,并采用多变量回归分析探究

目标:
我们进行该研究的目的是探究因为严重脓毒症的患者再次入院的频率、死亡率、医疗费用和相关风险因素。

设计:
该研究为观察性队列研究,且不采取任何干预措施。数据来源于医疗保健花销与利用数据库。

地点:
实验在美国三个州的所有非联邦医院进行。

参与人员:
2011年前两个季度的共43452位严重败血症的患者。

结果:
我们获得了严重脓毒症患者再入院的比例、相关花销和再入院后死亡率等相关数据,并采用多变量回归分析探究再入院患者及其入院特征。研究表明,在43452名败血症幸存者中,有26%的患者30天内重新入院,有48%的患者180天内再次入院。各种原因引起的再次入院患者的死亡率为8%,预计总花销超过11亿美元。有25%的患者需要在180天内多次入院,占所有患者入院次数的77%,30天内再次入院几率与以下因素呈正相关:年龄小于80岁(优势比为1.14; 95% 可信区间为 1.08–1.21)、黑人(优势比为1.18; 95% 可信区间为 1.10–1.26)、医保水平(优势比为1.21; 95% 可信区间为 1.13–1.30 )、医疗补助水平(优势比为1.34; 95% 可信区间为 1.23–1.46);然而女性患者因素会令再次入院频率降低(优势比为 0.92; 95% 可信区间为 0.87–0.96);严重败血症的并发症包括:恶性肿瘤(优势比为1.34; 95% 可信区间为1.24–1.45)、血管疾病(优势比为1.30; 95% 可信区间为1.15–1.46)、慢性肾病(优势比为1.24; 95% 可信区间为1.18–1.31)、肝病(优势比为1.22; 95% 可信区间为1.11–1.34)、充血性心力衰竭(优势比为1.14; 95% 可信区间为1.08–1.19)、肺部疾病(优势比为1.12; 95% 可信区间为1.06–1.18)、糖尿病(优势比为1.12; 95% 可信区间为1.07–1.17)。患者住院特征相关指标包括:住院时间延长、出院后去医疗保健机构继续治疗、医院年度严重败血症病例数量提高、再入院败血症患者死亡率提高。

结论:
败血症患者30天内和180天内的再入院情况普遍提高患者死亡率和医疗费用。患者的人口统计学资料和并发症同住院特征与患者30天内再入院比例相关。

原始出处
Goodwin AJ, Rice DA, Simpson KN, Ford DW.Frequency, cost, and risk factors of readmissions among severe sepsis survivors. Crit Care Med. 2015 Apr;43(4):738-46.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=327597, encodeId=5cb032e597e0, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jun 28 07:01:53 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28986, encodeId=672828986c7, content=不错的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Thu Jun 25 16:20:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516333, encodeId=a8481516333b9, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Mon Apr 06 14:43:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606462, encodeId=6ae81606462c0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Apr 06 14:43:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19546, encodeId=8dc319546d1, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=xiaoai5777, createdTime=Sun Apr 05 20:01:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
    2018-06-28 1e145228m78(暂无匿称)

    学习了.谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=327597, encodeId=5cb032e597e0, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jun 28 07:01:53 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28986, encodeId=672828986c7, content=不错的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Thu Jun 25 16:20:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516333, encodeId=a8481516333b9, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Mon Apr 06 14:43:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606462, encodeId=6ae81606462c0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Apr 06 14:43:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19546, encodeId=8dc319546d1, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=xiaoai5777, createdTime=Sun Apr 05 20:01:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
    2015-06-25 jjzouyan

    不错的研究

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=327597, encodeId=5cb032e597e0, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jun 28 07:01:53 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28986, encodeId=672828986c7, content=不错的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Thu Jun 25 16:20:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516333, encodeId=a8481516333b9, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Mon Apr 06 14:43:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606462, encodeId=6ae81606462c0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Apr 06 14:43:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19546, encodeId=8dc319546d1, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=xiaoai5777, createdTime=Sun Apr 05 20:01:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=327597, encodeId=5cb032e597e0, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jun 28 07:01:53 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28986, encodeId=672828986c7, content=不错的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Thu Jun 25 16:20:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516333, encodeId=a8481516333b9, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Mon Apr 06 14:43:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606462, encodeId=6ae81606462c0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Apr 06 14:43:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19546, encodeId=8dc319546d1, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=xiaoai5777, createdTime=Sun Apr 05 20:01:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=327597, encodeId=5cb032e597e0, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jun 28 07:01:53 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28986, encodeId=672828986c7, content=不错的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d231626576, createdName=jjzouyan, createdTime=Thu Jun 25 16:20:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516333, encodeId=a8481516333b9, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Mon Apr 06 14:43:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606462, encodeId=6ae81606462c0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Apr 06 14:43:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19546, encodeId=8dc319546d1, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=xiaoai5777, createdTime=Sun Apr 05 20:01:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
    2015-04-05 xiaoai5777

    好文章

    0

相关资讯

目前SIRS标准不适用于孕产妇败血症的诊断

在英国,败血症在2006–2008年期间是导致母体直接死亡的主要原因。美国围产期严重败血症和败血症导致的相关死亡在1998–2008年期间已增加了一倍。已有研究证明,败血症诊断和治疗的延迟会增加普通人群的死亡率。 而妊娠期生理变化可能是导致败血症诊断延迟的原因。美国胸科医师协会(ACCP)和危重病医学会(SCCM)将败血症的诊断定义为全身炎症反应综合征(SIRS)的继发感染。下列四项标准

北京宣武医院鉴定两例国内首次发现菌种

近日,首都医科大学宣武医院检验科细菌室应用分子生物学技术和质谱技术,鉴定出两例国内首次发现的菌种。 一例是在血流感染(败血症和菌血症)患者血培养中分离出的Rothia aeria。该菌2004年从俄罗斯空间站的水和空气中被首次分离和鉴定,并由此命名,迄今为止很少引起人类感染,全球共6例报道,此例在国内为首例报道。另一例是在尿路感染患者尿液中,分离鉴定出Candida niva

JCI:炎症疾病治疗新靶点--UCP2抑制剂有望治疗败血症

图示:UCP2-FASN调控脂质合成与NLRP3介导的caspase-1活化相关通路 败血症是目前内科重症监护病房内患者死亡的最主要原因之一,而机体针对外源微生物产生的过度免疫应答反应是导致败血症发生的原因。细胞脂类代谢的水平及其变化与免疫应答密切相关。但是,体内脂肪酸的生成为何能够调节免疫应答,其内在机制尚未被明确阐释。炎症小体NLRP3能够作为前炎性细胞因子的caspase-1途径依赖的

Immunity:重症感染致败血症治疗获新思路

中科院上海生化细胞所王红艳研究组发现,巨噬细胞受细菌感染或细菌脂多糖LPS刺激后,升高血管内皮生长因子受体3(VEGFR-3)的表达。VEGFR-3形成负反馈环路,抑制TLR4-NF-κB介导的炎症反应,降低细菌感染致败血症或内毒素休克的发生。相关论文日前在线发表于《免疫》Immunity杂志。 据介绍,宿主的巨噬细胞通过Toll样受体4(TLR4)识别细菌,并启动免疫应答。但TLR4信号通路是

EBioMedicine:英研究发现败血症快速诊断方法

近日研究发现,英属哥伦比亚大学的研究人员开发了一项新测试,该测试可以帮助医生预测患者是否在一小时内会发生严重的败血症,这样他们就可以立刻开始进行治疗。 败血症是一种由感染引起的综合症,它会导致人体器官衰竭以及每年高达五百万人的死亡。每年全世界约有1800万例败血症患者。 该发现可以减少确认病人是否患有败血症的诊断时间,也会增加他们对疗效的反馈。 “我们发现了一个基因标

PLoS One :血凝块能吸收细菌毒素?

在脊椎动物和节肢动物中,血液凝结包括聚集的血小板血栓的形成(细胞凝块)和由凝块的结构蛋白聚合形成的细胞外纤维状凝块,即哺乳动物中的纤维蛋白、甲壳类动物中的血浆脂蛋白和马蹄蟹(Limulus polyphemus)中的凝固素。这些凝块的功能是止血,另外,细胞外凝块还通过提供一种消极的抗菌障碍和微生物截留装置,发挥先天免疫系统的作用,直接作用于皮肤的伤口部位。来自美国加利福尼亚大学(

Baidu
map
Baidu
map
Baidu
map